Breast Cancer Metastatic clinical trials

Explore recruiting breast cancer metastatic clinical trials.

Recruiting breast cancer metastatic studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Breast Cancer Metastatic trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

"TUC-TOC": Tucatinib in combination with Oral Etoposide (VP16) - Trastuzumab in Patients with metastatic HER2+ Breast cancer after progression under Tucatinib-Capecitabine-Trastuzumab or toxicity related to capecitabine: a multicenter Phase II

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Study protocol title: A Phase I/II, open-label, multi-center trial of [177Lu]Lu-NeoB in combination with capecitabine in adult patients with gastrin releasing peptide receptor positive, estrogen receptor-positive, human epidermal growth receptor-2 negative metastatic breast cancer after progression on previous endocrine therapy in combination with a CDK4/6 inhibitor

Germany, Spain, France, Netherlands, Portugal, Italy

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Phase II study evaluating the addition of elacestrant, an oral selective estrogen receptor degrader (SERD), to standard-of-care olaparib in patients with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer with gBRCA1/2 mutations – ELEMENT

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Phase 2a Study of ZW25 in Combination with Palbociclib Plus Fulvestrant

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

An open-label, multicentric, phase 1 study to evaluate the safety, tolerability, and radiation dosimetry of endogenous radioligand therapy with (¹⁷⁷Lu)Lutetiumvipivotidtetraxetan in women with metastatic triple negative breast cancer (TNBC)

Germany

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Paclitaxel Versus Placebo + Paclitaxel as First-line Treatment for Patients with Histologically Confirmed, Locally Advanced (Inoperable) or Metastatic Triple-Negative Breast Cancer (TNBC) (CAPItello-290)

Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

Breast Cancer Metastatic trials by city

Breast Cancer Metastatic in Toronto Breast Cancer Metastatic in Vancouver Breast Cancer Metastatic in Montreal Breast Cancer Metastatic in Calgary Breast Cancer Metastatic in Edmonton Breast Cancer Metastatic in Ottawa Breast Cancer Metastatic in Winnipeg Breast Cancer Metastatic in Quebec City Breast Cancer Metastatic in Hamilton Breast Cancer Metastatic in Kitchener Breast Cancer Metastatic in London Breast Cancer Metastatic in Halifax Breast Cancer Metastatic in New York Breast Cancer Metastatic in Los Angeles Breast Cancer Metastatic in Chicago Breast Cancer Metastatic in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease